Voyager Therapeutics Stock News

Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Al Sandrock - Chief Executive Officer Todd Carter - Chief Scientific Officer Pe

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -7.02% and 112.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stoc

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announ

Some of the notable companies to have witnessed solid earnings acceleration as of now are Las Vegas Sands (LVS), Voyager Therapeutics (VYGR) & nCino (NCNO).

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today annou

Investors are taking profits on this red-hot stock this week.

In trying to deliver breakthrough, Voyager Therapeutics is able to ink multiple robust deals with reputable companies. The company is trying to tackle some of the most difficult to treat neurological

Voyager Therapeutics Inc (NASDAQ:VYGR) shares have jumped on the news that the biotechnology company has entered into a strategic collaboration with Neurocrine Biosciences (NASDAQ:NBIX) Inc to advance

Why is Voyager Therapeutics (NASDAQ: VYGR ) stock today up while Neurocrine Biosciences (NASDAQ: NBIX ) is down? Evidently, today's movement is because of a deal between the two biotechnology business

Shares of Voyager Therapeutics Inc. VYGR, +10.65% rallied 35% in premarket trading on Monday after the company announced a deal with Neurocrine Biosciences Inc. NBIX, +0.06% to develop and commerciali

Two new Breakout Stocks for Week 2 with better than 10% short-term upside potential and one Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. Momentum Gauge trading signal turned

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today annou

Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Alfred Sandrock - Chief Executive Officer Peter Pfreundschuh - Chief Financia

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 336.84% and 93.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-ass